DATE02/06/2017 - 06/06/2017
PLACEChicago, USA
DATE09/05/2017
PLACEAuditorium, Dexeus University Hospital
DATE06/04/2017
PLACECologne, Germany
Resistance to next-generation EGFR-inhibitors: consequences for clinical trial design Rosell R, MD, PhD
Overcoming resistance to targeted drugs: the clinical perspective Rosell R, MD, PhD
DATE01/04/2017 - 05/04/2017
PLACEWashington, USA
Routine Testing for KRAS mutations in cfDNA from blood of advanced cancer patients Garzón M, Mayo C, Jordana Ariza N, Balada i Bel A, García B, Villatoro S, Bertrán Alamillo J, Martínez Bueno A, Viteri Ramirez S, Pérez Rosado A, Morales Espinosa D, José Catalán M, Karachaliou N, Molina Vila M.A, Rosell R.
Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients Aguado C, Teixidó C, Giménez-Capitán A, de los Llanos Gil M, Rodríguez S, Karachaliou N, Viteri S, Peg V, Aldeguer E, Alonso L, Rosell R, Molina-Vila M.A
Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR Bertran-Alamillo J, Molina-Vila M.A, Teixidó C, Codony-Servat J, Giménez-Capitán J, Codony-Servat C, García-Román S, Aldeguer E, Rodríguez S, Rosell R
MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression Giménez-Capitán A, Teixidó C, Rodríguez S, Aguado C, Bertran-Alamillo J, Castellví J, Yeste Z, Perez A, Rosell R, Molina-Vila M.A
DATE20/03/2017 - 23/03/2017
PLACEDr. Rosell Oncology Institute